These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

955 related items for PubMed ID: 17944704

  • 1. In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole.
    Kaya AD, Kiraz N.
    Mycoses; 2007 Nov; 50(6):447-50. PubMed ID: 17944704
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Comparison of Sensititre YeastOne with the NCCLS M38-A microdilution method to determine the activity of amphotericin B, voriconazole, and itraconazole against clinical isolates of Aspergillus fumigatus.
    Guinea J, Peláez T, Alcalá L, Bouza E.
    Diagn Microbiol Infect Dis; 2006 Sep; 56(1):53-5. PubMed ID: 16650953
    [Abstract] [Full Text] [Related]

  • 4. Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies.
    Espinel-Ingroff A, Johnson E, Hockey H, Troke P.
    J Antimicrob Chemother; 2008 Mar; 61(3):616-20. PubMed ID: 18222957
    [Abstract] [Full Text] [Related]

  • 5. Correlation between the E test and the CLSI M-38 A microdilution method to determine the activity of amphotericin B, voriconazole, and itraconazole against clinical isolates of Aspergillus fumigatus.
    Guinea J, Peláez T, Alcalá L, Bouza E.
    Diagn Microbiol Infect Dis; 2007 Mar; 57(3):273-6. PubMed ID: 17141455
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Comparison of the activities of amphotericin B, itraconazole, and voriconazole against clinical and environmental isolates of Aspergillus species.
    Misra R, Malik A, Singhal S.
    Indian J Pathol Microbiol; 2011 Mar; 54(1):112-6. PubMed ID: 21393890
    [Abstract] [Full Text] [Related]

  • 9. Determination of antifungal drug susceptibilities of Aspergillus species by a fluorescence-based microplate assay.
    Balajee SA, Imhof A, Gribskov JL, Marr KA.
    J Antimicrob Chemother; 2005 Jan; 55(1):102-5. PubMed ID: 15546970
    [Abstract] [Full Text] [Related]

  • 10. Comparison of the Sensititre YeastOne and CLSI M38-A2 Microdilution Methods in Determining the Activity of Amphotericin B, Itraconazole, Voriconazole, and Posaconazole against Aspergillus Species.
    Wang HC, Hsieh MI, Choi PC, Wu CJ.
    J Clin Microbiol; 2018 Oct; 56(10):. PubMed ID: 30093391
    [Abstract] [Full Text] [Related]

  • 11. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
    Hsueh PR, Lau YJ, Chuang YC, Wan JH, Huang WK, Shyr JM, Yan JJ, Yu KW, Wu JJ, Ko WC, Yang YC, Liu YC, Teng LJ, Liu CY, Luh KT.
    Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
    [Abstract] [Full Text] [Related]

  • 12. In vitro activities of fluconazole, itraconazole and voriconazole against otomycotic fungal pathogens.
    Yenişehirli G, Bulut Y, Güven M, Günday E.
    J Laryngol Otol; 2009 Sep; 123(9):978-81. PubMed ID: 19454132
    [Abstract] [Full Text] [Related]

  • 13. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592).
    Manavathu EK, Cutright JL, Loebenberg D, Chandrasekar PH.
    J Antimicrob Chemother; 2000 Aug; 46(2):229-34. PubMed ID: 10933645
    [Abstract] [Full Text] [Related]

  • 14. In vitro activity of terbinafine and itraconazole against Aspergillus species isolated from otomycosis.
    Karaarslan A, Arikan S, Ozcan M, Ozcan KM.
    Mycoses; 2004 Aug; 47(7):284-7. PubMed ID: 15310330
    [Abstract] [Full Text] [Related]

  • 15. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi.
    Espinel-Ingroff A.
    J Clin Microbiol; 2001 Mar; 39(3):954-8. PubMed ID: 11230410
    [Abstract] [Full Text] [Related]

  • 16. Comparison of disk diffusion, E-test and broth microdilution test in determination of susceptibility of Aspergillus species to amphotericin B, itraconazole and voriconazole.
    Ozkutuk A, Ergon C, Metin DY, Yucesoy M, Polat SH.
    J Chemother; 2008 Feb; 20(1):87-92. PubMed ID: 18343749
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. In vitro susceptibility testing of Aspergillus spp. against voriconazole, itraconazole, posaconazole, amphotericin B and caspofungin.
    Shi JY, Xu YC, Shi Y, Lü HX, Liu Y, Zhao WS, Chen DM, Xi LY, Zhou X, Wang H, Guo LN.
    Chin Med J (Engl); 2010 Oct; 123(19):2706-9. PubMed ID: 21034656
    [Abstract] [Full Text] [Related]

  • 19. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
    Johnson E, Espinel-Ingroff A, Szekely A, Hockey H, Troke P.
    Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.